Research & Development

Transfection Reagents for

Research & Development Use


We developed broadly acting transfection reagents to modify cells with plasmid DNA and siRNA. The transfection reagents have been optimized for a range of cell phenotypes, including 293T embryonic kidney cells, MDA231, MDA435 and MCF-7 breast cancer cells, K562 chronic myeloid leukemia cells, THP-1 and KG1 acute myeloid leukemia cells, NALM-6 and MOLM-13 acute lymphocytic leukemia cells, U937 lymphoma cells, primary leukocytes, fibroblasts, smooth muscle cells, endothelial cells and mesenchymal stem cells (human and rodent derived). For specific applications, we offer the following products :

ALL-Fect

This product is designed for transfection of anchorage-dependent cells with plasmid DNA and siRNA. It is particularly suitable for highly differentiated cells such as mesenchymal stem cells from cord blood and bone marrow, smooth muscle cells, and endothelial cells.

Download ALL-Fect Brochure
Benefits of the reagent :
  • High transfection efficiency
    Provides 2 to 3-fold higher efficacy under serum conditions
  • Simple Protocol
    No need to change tissue culture medium during transfection
  • Toxicity
    Less toxic compared to commercial transfection reagents, leading to better retention of normal cellular physiology
References :
  • Hsu and Uludağ. Biomaterials (2012) 33: 7834-7848.
  • Remant Bahadur et al., J. Materials Chemistry B (2015) 3: 3972-3982.
  • Wang et al., J. Surgical Research (2013) 183: 8-17.


Typical performance of All-Fect for transfecting cord-blood derived mesenchymal stem cells with a GFP plasmid. The study compared the performance of All-Fect against a leading lipofection reagent under conditions optimized for each reagent. The extent of transgene expression was quantitated by flow cytometry, based on the extent of EGFP expression in arbitrary units. Typical fluorescent micrographs showing GFP expression after transfection are provided on the top.

293-Fect

This product is designed for transfection of attachment dependent and rapidly dividing cells such as 293T cells, with plasmid DNA. These cells are routinely transfected for small scale production of proteins for R&D purposes, as well as industrial scale production of proteins for commercial and clinical uses. This reagent is also effective with other attachment-dependent cells such as CHO cells and breast cancer MDA-231 cells.

Download 293-Fect Brochure
Benefits of the reagent :
  • High transfection efficiency
    Provides 2 to 3-fold higher efficacy under serum conditions
  • Simple Protocol
    No need to change tissue culture medium during transfection
  • Toxicity
    Less toxic compared to commercial transfecting reagents, leading to better protein yields from the transfected cells
  • Stability
    Long term stability at room temperature
References :
  • Clements et al., Clinical Orthopeadics and Related Research (2009) 467: 3129-3137.
  • Naemnark et al., Molecular Pharmaceutics (2009) 6: 1798-1815.




Typical performance of 293-Fect for transfecting attachment-dependent 293 cells with a GFP plasmid is shown in the figure. The study compared the performance of 293-Fect against a leading lipofection reagent and linear PEI (L-PEI; 44 kDa) under conditions optimized for each reagent. Typical fluorescent micrographs showing EGFP expression after transfection (A). The extent of transgene expression was quantitated by flow cytometry, based on the percentage of cells expressing the GFP gene (B) and the extent of GFP expression in arbitrary units (C).

Leu-Fect-A & B

These products are designed for transfection of attachment-independent (suspension growing) cells and are specifically tailored for siRNA delivery. We offer two different formulations (Leu-Fect A and Leu Fect B) that are effective in different types of attachment-independent cells. We recommend the users to test the efficacy of both reagents in their particular cell type and choose the right formulation for long-term use.

Download Leu-Fect-A Brochure
Benefits of the reagent :
  • High transfection efficiency
    Provides 2 to 3-fold higher efficacy under serum conditions
  • Simple Protocol
    No need to change tissue culture medium during transfection
  • Toxicity
    Less toxic compared to commercial transfecting reagents, leading to better protein yields from the transfected cells
References :
  • Gul-Uludag et al. Leukemia Research (2014) 38: 1299–1308.
  • Landry et al. J. Controlled Release (2016) 224: 8-21.
  • Valencia-Serna et al. J. Controlled Release (2013) 172: 495-503.



Uptake of Leu-Fect/FAM-siRNA complexes in K562 cells in vitro (A) and in vivo K562 tumors (B). Typical performance of Leu-Fect for transfecting K562 chronic myeloid leukemia (CML) cells with a specific siRNA against Bcr-Abl. The study compared the performance of Leu-Fect against a leading lipofection reagent and branched PEI (PEI25; 25 kDa) under conditions optimized for each reagent. The extent of gene silencing was quantitated by qPCR (C). The functional outcome, in the form of inhibition of cell growth, was assessed by the MTT Assay and expressed relative to non-treated cells (D).

In Vivo DNA-Fect

This product is designed for delivery of plasmid DNA in animal models. It is a cost-effective alternative to PEI-based reagents marketed for in vivo applications, with improved transfection efficiency. The application of current reagents is usually limited by their toxicity, which either limits the expression of the transgenes or alters the physiological response in the vicinity of the administered agents. The biocompatibility of In Vivo DNA-Fect minimally alters the cellular physiology, allowing a better response of the expressed transgenes.

Download In Vivo DNA-Fect Brochure
Benefits of the reagent :
  • High transfection efficiency
    Provides 2 to 3-fold higher efficacy under serum conditions
  • Simple Protocol
    Can be administered with simple formulations such as saline
  • Toxicity
    Less toxic compared to commercial transfecting reagents, leading to better protein yields from the transfected cells
References :
  • Rose et al., Biomaterials Science (2014) 2: 833-842.
  • Rose et al., Biomaterials (2012) 33: 3363-3374.



Typical performance of In Vivo DNA-Fect for transfecting tissues with two separate GFP plasmids at the rat subcutaneous site is shown in the figure. The study compared the performance of In Vivo DNA-Fect against branched PEI (PEI25; 25 kDa), after the corresponding complexes were implanted in gelatin sponges for 14 days. The extent of transgene expression was assessed by histology of explanted tissues, followed by the fluorescent microscopy.

In Vivo RNA-Fect

This product is designed for delivery of siRNA in mice tumor models. It can be directly administered into a specific site (e.g., intratumorally), or systematically. It is a cost-effective alternative to PEI-based reagents marketed for in vivo applications.

Download In Vivo DNA-Fect Brochure
Benefits of the reagent :
  • High transfection efficiency
    Provides effective transfection under physiological conditions
  • Simple Protocol
    siRNA particles can be prepared in saline suitable for administration
  • Toxicity
    Less toxic compared to other commercial transfecting reagents
References :
  • Aliabadi et al., J. Controlled Release (2013) 172: 219-228.
  • Alshamsan et al., Translational Oncology (2011) 4: 178-188.
  • Abbasi et al., Pharmaceutical Research (2011) 28: 2516-2529.


Tumor growth profiles as a result of siRNA delivery with In Vivo RNA-Fect is shown in the figure. The tumors were left untreated, or treated with scrambled and therapeutic siRNAs formulated with the transfection reagent. Formulations injected intratumorally (A). Formulations injected intraperitoneally (B).